Tango Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(92,632) | $(70,981) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation | 1,879 | 1,798 |
| Noncash operating lease expense | 2,791 | 2,692 |
| Stock-based compensation | 21,435 | 14,200 |
| Accretion on marketable securities | (3,761) | (1,030) |
| Other, net | 33 | 22 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 2,000 |
| Prepaid expenses and other current assets | 1,259 | (3,582) |
| Other long-term assets | 34 | (42) |
| Accounts payable | 1,323 | (1,617) |
| Accrued expenses and other liabilities | (357) | (6,026) |
| Operating lease liabilities | (1,006) | (1,853) |
| Deferred revenue | (25,852) | (26,096) |
| Net cash used in operating activities | (94,854) | (90,515) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (630) | (1,300) |
| Sales and maturities of marketable securities | 243,035 | 268,423 |
| Purchases of marketable securities | (208,339) | (259,549) |
| Net cash provided by investing activities | 34,066 | 7,574 |
| Cash flows from financing activities | ||
| Proceeds from at-the-market offerings, net of issuance costs | 41,723 | — |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | — | 79,839 |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP | 4,972 | 1,100 |
| Net cash provided by financing activities | 46,695 | 80,939 |
| Net change in cash, cash equivalents and restricted cash | (14,093) | (2,002) |
| Cash, cash equivalents and restricted cash, beginning of period | 69,808 | 63,958 |
| Cash, cash equivalents and restricted cash, end of period | $55,715 | $61,956 |
| Supplemental cash flow information: | ||
| Cash paid for leases | $3,731 | $4,116 |
| Supplemental disclosure of noncash investing and financing activity: | ||
| Revaluation of right-of-use asset and lease liability upon lease remeasurement | $497 | $(228) |
| Financing offering costs included in accounts payable and accrued expenses | $— | $63 |
| Capital expenditures included in accounts payable and accrued expenses | $3 | $— |
| Operating lease liabilities from obtaining right-of-use assets | $210 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.